Rise in Medicare Costs Blamed on Obesity
Posted on: Tuesday, 22 August 2006, 12:00 CDT
A study blames most of the growth in U.S. Medicare costs the past 15 years on treating problems related to obesity and certain chronic conditions.
The study done at Atlanta's Emory University said the rate of obesity among Medicare patients doubled from 1987 to 2002, and spending on those individuals more than doubled.
The findings by economists Kenneth Thorpe and David Howard appear on the Web site of the journal Health Affairs, reports USA Today.
What this study tells us is that we need to aggressively put in place interventions to deal with obesity and chronic disease prevalence among the elderly to control spending, said Thorpe.
The study said spending on medical care for obese Medicare patients was 24.8 percent of the program's budget in 2002, compared to 9.4 percent in 1987.
The researchers said doctors also have become more aggressive in treating patients who have a cluster of cardiovascular-related risk factors such as diabetes, high blood pressure or low levels of good cholesterol.
Last year's total Medicare expenditures were $336 billion but this projected to increase rapidly as the first wave of the 75 million baby boomers reaches retirement age and Medicare eligibility in 2010, the report said.
Source: United Press International
Related Articles
- SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
- New Study Shows Morbidly Obese Workforce Has Higher Prevalence of 100+ Diseases and Conditions
- Results From Largest Statin Study of Patients With Alzheimer's Disease Show Lipitor(R) Has No Significant Impact on Disease
- ZymoGenetics Releases Preliminary Findings From Atacicept (TACI-Ig) Phase 1b Studies in Patients With Lupus
- UB, BlueCross BlueShield Launch Study of Nonsurgical Obesity Treatments
- Medicare to Cover Certain Obesity Surgeries Across U.S.
- Web Seminar Offered -- ''EHR Case Study: Delivering Patient Data Today''
- ZymoGenetics Reports Preliminary Positive Results From TACI-Ig Phase 1b Study in Patients With Rheumatoid Arthritis
- New Study Suggests Patients With Schizophrenia Improved With Treatment Change to RISPERDAL(R) CONSTA(R)
- IL-1 Trap Shows Positive Results in Study of Patients With Inflammatory Disease
User Comments (0)

RSS Feeds